# Cytospire Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cytospire-therapeutics

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.cytospire.com/
- Total disclosed funding: $83M
- Latest round: Series A (May 5, 2026)
- Investors on record: 10

## About

Cytospire Therapeutics Limited is a biopharmaceutical company focused on developing innovative multispecific antibodies to enhance cancer therapy efficacy. Based in London, UK, it aims to harness immune systems for improved patient outcomes. Cytospire Therapeutics Limited specializes in the development of next-generation multispecific antibodies, focusing on enhancing ?d T cell engagers in cancer therapy. The company was founded in 2023 by Natalie Mount (CEO) and Mark Uden (CTO) and is headquartered in London, UK. It has completed a total of 2 deals, with its latest funding round being a Series A, raising £61 million (GBP) led by 4BIO Capital Partners. Other investors include Abingworth, British Business Bank, Criteria Bio Ventures, LifeArc, Medical Incubator Japan, Modi Ventures, Pathway Bioventures, Servier, and Sound Bioventures. The funding will support the advancement of its immune cell engagers into clinical trials.Cytospire Therapeutics specializes in the development of next-generation multispecific antibodies, specifically tailored to enhance the efficacy of ?d T cell engagers in cancer therapy. These innovative products harness the innate and adaptive immune systems, providing a more targeted and safer alternative to existing CD3-based engagers. By directing key effector cells to combat cancer, Cytospire addresses various cancer types and improves patient outcomes through its advanced therapeutic solutions. The products primarily target oncologists, healthcare institutions, and pharmaceutical partners, catering to markets in North America, Europe, and Asia.Cytospire Therapeutics has successfully secured significant investment through an oversubscribed £61 million (GBP) Series A financing round, aimed at advancing its pioneering pipeline of immune cell engagers into clinical trials. The company generates revenue through partnerships with pharmaceutical companies and healthcare providers, and potentially direct B2B sales of its therapeutic products once commercially available. Revenue strategies may include subscription models for ongoing access to novel therapies or milestone payments associated with successful clinical advancements. The flagship products, focused on enhancing ?d T cell engagement, are expected to command premium pricing due to their novel technology and therapeutic potential. Cytospire Therapeutics plans to leverage its recent funding to accelerate the development and clinical trials of its innovative multispecific antibodies. The company aims to introduce new products targeting various cancer types and is exploring expansion into North America, Europe, and Asia. The recent Series A funding, amounting to £61 million (GBP), will be utilized to support these strategic initiatives and enhance its research capabilities, ensuring a robust pipeline for future growth.

## Funding rounds

- Series A, May 5, 2026, $83M — Abingworth, 4BIO Capital Partners, Medical Incubator Japan, Servier, Pathway Bioventures, LifeArc, Sound Bioventures, Modi Ventures, Criteria Bio Ventures, British Business Bank

## Investors

- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series A
- 4BIO Capital Partners (https://capitalatlas.ai/funds/4bio-capital-partners) — Series A
- Medical Incubator Japan (https://capitalatlas.ai/funds/medical-incubator-japan) — Series A
- Servier — Series A
- Pathway Bioventures (https://capitalatlas.ai/funds/pathway-bioventures) — Series A
- LifeArc (https://capitalatlas.ai/funds/lifearc) — Series A
- Sound Bioventures (https://capitalatlas.ai/funds/sound-bioventures) — Series A
- Modi Ventures (https://capitalatlas.ai/funds/modi-ventures) — Series A
- Criteria Bio Ventures (https://capitalatlas.ai/funds/criteria-bio-ventures) — Series A
- British Business Bank (https://capitalatlas.ai/funds/british-business-bank) — Series A